Expression of hypoxia-inducible 2 (HIG2) protein in uterine cancer

S. Nishimura, H. Tsuda, H. Nomura, F. Kataoka, T. Chiyoda, H. Tanaka, K. Tanaka, N. Susumu, D. Aoki

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

For both cervical cancer (UCC) and endometrial cancer (EMC) there are no effective prognostic markers. In this study, we evaluated HIG2 protein expression in 332 uterine cancers (186 UCCs and 146 EMCs) and examined the relationship between HIG2 protein expression and clinical factors, including prognosis. Totally, HIG2 expression was detected in 58% of UCC and 66% of EMC. However, there was no significant relationship between HIG2 expression and age, clinical stage and histology in either UCC or EMC. In addition, HIG2 protein expression was not related to prognosis of UCC or EMC. The positivity rate of HIG2 protein was 56% and 61% in early-stage UCC and EMC, respectively and 67% in non-squamous cell carcinoma of UCC. The positivity rate of HIG2 protein was high even in early-stage UCC and EMC.

Original languageEnglish
Pages (from-to)146-149
Number of pages4
JournalEuropean Journal of Gynaecological Oncology
Volume32
Issue number2
Publication statusPublished - 2011

Keywords

  • Adenocarcinoma
  • Cervical cancer
  • Endometrial cancer
  • HIG2

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'Expression of hypoxia-inducible 2 (HIG2) protein in uterine cancer'. Together they form a unique fingerprint.

  • Cite this

    Nishimura, S., Tsuda, H., Nomura, H., Kataoka, F., Chiyoda, T., Tanaka, H., Tanaka, K., Susumu, N., & Aoki, D. (2011). Expression of hypoxia-inducible 2 (HIG2) protein in uterine cancer. European Journal of Gynaecological Oncology, 32(2), 146-149.